<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03729817</url>
  </required_header>
  <id_info>
    <org_study_id>2020</org_study_id>
    <nct_id>NCT03729817</nct_id>
  </id_info>
  <brief_title>VERiTAS II REFRESHED</brief_title>
  <official_title>Vertebrobasilar Stroke and Risk of Transient Ischemic Attack and Stroke (VERiTAS) II - Restoring Flow by Revascularization With Submaximal Angioplasty in Hemodynamic Intracranial Atherosclerotic Disease (REFRESHED) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent prospective observational data has established that hemodynamic compromise identifies&#xD;
      a high risk subgroup of patients with symptomatic intracranial atherosclerotic disease. The&#xD;
      currently proposed study aims to determine if an endovascular intervention, submaximal&#xD;
      balloon angioplasty, can be performed with adequate safety in this high risk subgroup of&#xD;
      hemodynamically-compromised patients with intracranial atherosclerotic stenosis. The study&#xD;
      will also examine as secondary aims, the effect of the intervention on hemodynamics and on&#xD;
      subsequent in-territory ischemic events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VERiTAS II REFRESHED is a prospective two-arm randomized multi-center pilot study to assess&#xD;
      the safety of submaximal balloon angioplasty in conjunction with intensive medical therapy in&#xD;
      patients with hemodynamically-compromised symptomatic 70-99% atherosclerotic intracranial&#xD;
      stenosis (ICAS). This study builds on lines of evidence from prior prospective studies that&#xD;
      established the markedly elevated risk of subsequent stroke in ICAS patients with hemodynamic&#xD;
      compromise, and preliminary data from small case series that support submaximal angioplasty&#xD;
      as a potentially safe option for revascularization. The primary objective of the current&#xD;
      study is to determine the safety of submaximal balloon angioplasty for treatment of&#xD;
      hemodynamically-compromised symptomatic ICAS. The secondary objectives are to obtain&#xD;
      preliminary estimates for the risk of subsequent in-territory stroke at one year in patients&#xD;
      treated with submaximal angioplasty in conjunction with intensive medical therapy and in&#xD;
      patients treated with intensive medical therapy alone, to evaluate the hemodynamic effect of&#xD;
      submaximal balloon angioplasty on distal blood flow, and to examine the hemodynamic&#xD;
      durability of submaximal balloon angioplasty over follow-up.&#xD;
&#xD;
      A total of 196 patients will be enrolled in this open-label study and randomized 2:1 to&#xD;
      receive the submaximal angioplasty intervention in conjunction with intensive medical therapy&#xD;
      or intensive medical therapy alone. Patients with stroke attributable to ICAS serve as the&#xD;
      source population for the study, and will be identified as inpatients or outpatients at&#xD;
      participating centers or their referring sites. Patients with recently (within 30 days prior&#xD;
      to enrollment) symptomatic 70-99% ICAS of the intracranial internal carotid (ICA), middle&#xD;
      cerebral (MCA), vertebral (VA) or basilar (BA) artery will first be identified by a standard&#xD;
      of care screening imaging modality (e.g. CTA, MRA, TCD). If the patient is eligible based on&#xD;
      available inclusion/exclusion criteria, informed consent will be obtained and MRI/&#xD;
      quantitative magnetic resonance angiography (QMRA) will be performed (if not already as&#xD;
      standard care); patients demonstrating evidence of hemodynamic compromise based on borderzone&#xD;
      infarct pattern for the anterior circulation (ICA and MCA) and by low flow state on QMRA for&#xD;
      the posterior circulation (VA and BA) will be considered eligible. QMRA will be used for&#xD;
      determination of eligibility in posterior circulation ICAS patients, but will be performed in&#xD;
      both anterior and posterior circulation patients as a baseline for hemodynamic comparison&#xD;
      post-procedure. The patient will then undergo CTA (if not performed already as standard care)&#xD;
      to confirm eligible intracranial ICAS, and will be randomized 2:1 to undergo either&#xD;
      submaximal angioplasty plus intensive medical therapy or intensive medical therapy alone.&#xD;
&#xD;
      Those randomized to submaximal angioplasty will undergo the procedure in accordance with the&#xD;
      study protocol within 48 hours of randomization, followed by SAMMPRIS regimen intensive&#xD;
      medical therapy, including initial dual antiplatelet therapy (aspirin and clopidogrel for 3&#xD;
      months followed by aspirin monotherapy), and targeting primary and secondary stroke risk&#xD;
      factors. Those randomized to intensive medical therapy alone will receive the same SAMMPRIS&#xD;
      regimen intensive medical therapy. Assistance in achieving the risk factor goals will be&#xD;
      provided by an INTERVENT lifestyle coach, who will call the participant by phone at 1, 3, 5,&#xD;
      7, 9, 11 weeks, and then every 4 weeks throughout follow-up. On a scheduled basis, INTERVENT&#xD;
      will send a report of the participant's progress and goals for risk factor modification to&#xD;
      the participant and study coordinator/ study neurologist. Participants will have follow-up&#xD;
      for a total of one year. All participants will have clinical visits at 1, 4, 8, and 12&#xD;
      months, performed by local study personnel not directly involved with the angioplasty&#xD;
      procedure. The study visits will include assessment of neurological, functional and cognitive&#xD;
      status, as well as status of primary and secondary stroke risk factor control. For those&#xD;
      randomized to submaximal angioplasty, QMRA will be performed post procedure and at 12 months;&#xD;
      the follow-up QMRA results will be blinded to the local study personnel and patients. The&#xD;
      main outcomes of interest are: (1) any periprocedural (within 30 day) stroke or death; (2)&#xD;
      stroke in the symptomatic vessel territory; and (3) distal flow status post procedure and at&#xD;
      follow-up (using QMRA). Additional measured endpoints will include cerebral infarct on&#xD;
      imaging associated with temporary signs, restenosis and functional and cognitive outcomes at&#xD;
      follow-up.&#xD;
&#xD;
      The sample size calculations have been based on a confidence interval (CI) approach aimed at&#xD;
      determining if the intervention can be performed with a clinically specified periprocedural&#xD;
      event rate of 5% (90% CI 2,10%), in order to establish sufficient periprocedural safety of&#xD;
      submaximal angioplasty to warrant further investigation in a future phase 2/3 randomized&#xD;
      trial. The sample size calculation assumes a CI approach around the stroke/death event rate&#xD;
      at 30 days; for the presumed event rate of 5%, a sample size of N=117 would yield a 90% CI of&#xD;
      (2%,10%). Adjusting for the inflation factor 1.02 due to a planned interim analysis and a 4%&#xD;
      attrition rate for the 30-day follow-up, 124 patients are required to undergo submaximal&#xD;
      angioplasty for analysis of the primary safety endpoint. With an anticipated 5% ineligibility&#xD;
      for submaximal angioplasty at time of catheter angiography performed for the procedure, a&#xD;
      total of 131 patients will be randomized to submaximal angioplasty to obtain the safety&#xD;
      dataset of 124 patients. An interim analysis of safety is planned with a stopping rule if&#xD;
      30-day periprocedural risk exceeds 5% (i.e. lower bound of CI of observed estimate exceeds&#xD;
      the threshold). To ensure that the intervention is stopped early if it is harmful, the timing&#xD;
      of the interim analysis will be flexible, to occur once 30 day follow-up has been completed&#xD;
      on one third of submaximal angioplasty patients (41 patients) or alternatively, when 12&#xD;
      events are observed, whichever comes first; the number of events, 12, has been specified as&#xD;
      the minimal event number which would result in the lower bound of the 90% CI exceeding 5% and&#xD;
      thus claim a &gt;5% event rate. As related to the study's go/no go criteria for a future trial,&#xD;
      our definitive no go parameter is proposed as the lower bound of the observed pre-specified&#xD;
      CI exceeding the safety (30-day periprocedural risk) threshold of 5%. Other outcomes from the&#xD;
      study (i.e. the secondary clinical and hemodynamic endpoints at 12 months) would also be&#xD;
      taken into account in determining whether the procedure warrants additional study in a future&#xD;
      seamless phase 2/3 trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be recruited and randomized 2:1 into a two-arm study undergoing intervention in conjunction with intensive medical therapy or intensive medical therapy alone</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Safety</measure>
    <time_frame>30 days</time_frame>
    <description>Any stroke (ischemic or hemorrhagic), or death, within 30 days following submaximal angioplasty</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Efficacy</measure>
    <time_frame>1 year</time_frame>
    <description>Any stroke/death within 30 days or ischemic stroke in the symptomatic vessel territory at one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Success</measure>
    <time_frame>post procedure (within 7 days)</time_frame>
    <description>Initial hemodynamic effect of submaximal balloon angioplasty on treated vessel flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Durability</measure>
    <time_frame>1 year</time_frame>
    <description>Hemodynamic durability of submaximal balloon angioplasty at follow-up in the treated vessel at follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Intracranial Atherosclerotic Disease</condition>
  <condition>Stroke</condition>
  <condition>Angioplasty, Balloon</condition>
  <condition>Hemodynamics</condition>
  <condition>Device Safety</condition>
  <arm_group>
    <arm_group_label>Submaximal balloon angioplasty plus intensive medical therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endovascular intervention with submaximal balloon angioplasty plus intensive medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive medical therapy alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Concurrent calibration control treated with intensive medical therapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Submaximal balloon angioplasty</intervention_name>
    <description>An endovascular procedure involving inflation of a balloon catheter undersized to 50-75% of normal vessel diameter to perform angioplasty of a stenotic blood vessel segment, with the goal of increasing blood flow.</description>
    <arm_group_label>Submaximal balloon angioplasty plus intensive medical therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensive medical therapy</intervention_name>
    <description>SAMMPRIS regimen intensive medical therapy</description>
    <arm_group_label>Intensive medical therapy alone</arm_group_label>
    <arm_group_label>Submaximal balloon angioplasty plus intensive medical therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must meet all inclusion criteria for enrollment into the study&#xD;
&#xD;
          -  Non-severe recent stroke (within 30 days) attributed to 70-99% stenosis of&#xD;
             intracranial artery (internal carotid, middle cerebral, vertebral, basilar); must be&#xD;
             confirmed by CTA (or DSA if already available) for enrollment into the trial.&#xD;
&#xD;
          -  Hemodynamic compromise based on borderzone infarct pattern for the anterior&#xD;
             circulation (ICA and MCA) and by low flow state on QMRA for the posterior circulation&#xD;
             (VA and BA).&#xD;
&#xD;
          -  Target vessel with minimal nominal diameter of 2mm&#xD;
&#xD;
          -  Target length of stenosis &lt;18mm&#xD;
&#xD;
          -  Symptoms within 30 days of enrollment&#xD;
&#xD;
          -  Age &gt;=30 and &lt;=90 years old&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from study&#xD;
        participation&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  Major disabling stroke mRS &gt;3; progressive or fluctuating deficit within 24 hours&#xD;
&#xD;
          -  Hemorrhagic infarction (based on CT) within 14 days of enrollment&#xD;
&#xD;
          -  Any large stroke (&gt;5cm) to be at risk for hemorrhagic conversion&#xD;
&#xD;
        Medical:&#xD;
&#xD;
          -  Any neurological disease which would confound follow-up assessment&#xD;
&#xD;
          -  Any co-morbid disease condition with &lt;12 month life expectancy&#xD;
&#xD;
          -  Known cardiac disease associated with elevated cardioembolic risk, specifically,&#xD;
             atrial fibrillation, prosthetic valve, endocarditis, left atrial/ventricular thrombus,&#xD;
             cardiomyopathy with EF&lt;25%, cardiac myxoma&#xD;
&#xD;
          -  Blood dyscrasias, specifically polycythemia vera, essential thrombocytosis, sickle&#xD;
             cell disease&#xD;
&#xD;
          -  Active bleeding diathesis, h/o major systemic hemorrhage within 30 days, active PUD,&#xD;
             platelets&lt;100K (severe liver impairment (AST or ALT&gt;3 x normal, cirrhosis)&#xD;
&#xD;
        Target lesion:&#xD;
&#xD;
          -  Non-atherosclerotic stenosis including dissection, fibromuscular dysplasia,&#xD;
             vasculitis, radiation induced vasculopathy, suspected recanalized embolus, suspected&#xD;
             vasospastic process&#xD;
&#xD;
          -  Mori C classification of stenosis(i.e. diffuse lesion, extremely angulated &gt;90‚Å∞,&#xD;
             excessive proximal tortuosity)Previous treatment of target lesion with stent,&#xD;
             angioplasty or other mechanical device&#xD;
&#xD;
          -  Extracranial vertebral artery or carotid artery tortuosity, stenosis or occlusion&#xD;
             prohibiting access to the target lesion (Extracranial disease is not exclusionary if&#xD;
             does not prohibit access to target lesion)&#xD;
&#xD;
        Participant:&#xD;
&#xD;
          -  Unable or unwilling to undergo MRI&#xD;
&#xD;
          -  Unable to undergo cerebral angiography&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Concurrent participation in another study which would conflict with the current study&#xD;
&#xD;
          -  Allergy or contraindication to aspirin or Plavix&#xD;
&#xD;
          -  Indication for warfarin or NOAC beyond enrollment (e.g. venous thrombo-embolism,&#xD;
             atrial fibrillation)&#xD;
&#xD;
          -  Thrombolytic therapy within 24 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sepideh Amin-Hanjani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Siddiqui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanya Turan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sepideh Amin-Hanjani, MD</last_name>
    <phone>312-355-2050</phone>
    <email>hanjani@uic.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University oif Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Sepideh Amin-Hanjani</investigator_full_name>
    <investigator_title>Professor, Department of Neurosurgery, University of Illinois at Chicago</investigator_title>
  </responsible_party>
  <keyword>Intracranial atherosclerotic disease</keyword>
  <keyword>Stroke</keyword>
  <keyword>Angioplasty, Balloon</keyword>
  <keyword>Hemodynamics</keyword>
  <keyword>Device Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

